Jevtana (Cabazitaxel)

• Cabazitaxel is approved for patients with metastatic castration‑resistant prostate cancer (mCRPC) whose disease has progressed following treatment with docetaxel, providing a chemotherapy option when first‑line taxane therapy is no longer effective.
• Metastatic castration‑resistant prostate cancer after docetaxel: improves overall survival and disease control in advanced disease.
• Advanced prostate cancer after docetaxel failure: serves as a second‑line taxane to extend survival and delay progression.

• Cabazitaxel binds to the β‑tubulin subunit of microtubules, promoting polymerization and stabilizing the microtubule network. This prevents depolymerization during cell division, leading to mitotic arrest and apoptosis of rapidly proliferating cancer cells. Its affinity for tubulin is retained even in cells expressing multidrug‑resistance proteins, distinguishing it from other taxanes.

Cabazitaxel, like other taxanes, is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: a marked reduction in neutrophils that can increase susceptibility to bacterial infections.
• Fatigue: persistent tiredness that may limit physical activity and affect quality of life.
• Diarrhea: frequent loose stools that may lead to dehydration if not managed.
• Alopecia: loss of hair on the scalp and body, typically reversible after treatment.

Serious or Rare Side Effects

• Febrile neutropenia: fever accompanying neutropenia, a medical emergency that may require hospitalization and antibiotics.
• Peripheral neuropathy: nerve damage causing tingling, numbness, burning sensations, or pain, potentially affecting hands and feet.
• Hypersensitivity reactions: allergic responses ranging from rash and flushing to rare anaphylactic shock.

When using Cabazitaxel, clinicians should observe specific precautions to minimize risks and ensure safe handling.

• Patient selection: assess prior chemotherapy exposure and overall performance status before initiating therapy.
• Hematologic monitoring: perform regular complete blood counts to detect neutropenia or anemia early.
• Infection risk: monitor for signs of infection and provide prophylactic antibiotics as indicated.
• Liver function: evaluate hepatic enzymes because impaired function may increase drug exposure.
• Pregnancy and lactation: avoid use in pregnant or breastfeeding women due to unknown fetal risk.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel may interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: agents such as rifampin can markedly reduce Cabazitaxel plasma levels.
• Concurrent use with other myelosuppressive chemotherapy: increases risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors: drugs like ketoconazole may raise Cabazitaxel exposure and require dose adjustment.
• Anticoagulants: heightened bleeding risk when combined with agents affecting platelet function.
• Supportive growth factors: use of G‑CSF may be needed to manage neutropenia but should be coordinated with oncology care.